Literature DB >> 33368536

Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.

Jorge E Cortes1, Priyanka Mehta2.   

Abstract

Treatment of older patients with AML remains challenging. Although age, performance status, and comorbidities are commonly employed to determine fitness for intensive treatment, several studies have demonstrated improved outcomes with treatment in older and classically unfit patients, highlighting the importance of other disease-related and patient-related factors that have prognostic value for treatment outcome in AML. However, consistent and objective assessments for fitness are lacking. Multi-parameter geriatric assessment tools offer more comprehensive evaluation, but are limited by the required resources and lack of standardization and consensus regarding prognostic value. These assessments are particularly important considering the emerging new AML therapies that represent a spectrum of intensities. Patients should therefore be evaluated holistically for fitness to receive a specific treatment, with the aim of providing individualized care, and such definitions of fitness should also consistently be applied to clinical trials. This review will examine evolving criteria for the determination of fitness among AML patients and discuss treatment options for older and/or unfit patients with AML.
© 2020 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33368536      PMCID: PMC7986910          DOI: 10.1002/ajh.26079

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  49 in total

1.  Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment.

Authors:  Gunnar Juliusson
Journal:  Blood       Date:  2011-03-24       Impact factor: 22.113

2.  Early mortality and survival in older adults with acute myeloid leukemia.

Authors:  Manisha Pant; Vijaya Raj Bhatt
Journal:  Int J Hematol Oncol       Date:  2017-11-20

3.  Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Authors:  Michael R Savona; Daniel A Pollyea; Wendy Stock; Vivian G Oehler; Mark A Schroeder; Jeffrey Lancet; James McCloskey; Hagop M Kantarjian; Weidong Wendy Ma; M Naveed Shaik; A Douglas Laird; Mirjana Zeremski; Ashleigh O'Connell; Geoffrey Chan; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

4.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

Review 5.  More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate.

Authors:  Heidi D Klepin; Elihu Estey; Tapan Kadia
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

6.  Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.

Authors:  Anne Etienne; Benjamin Esterni; Aude Charbonnier; Marie-Joëlle Mozziconacci; Christine Arnoulet; Diane Coso; Brigitte Puig; Jean-Albert Gastaut; Dominique Maraninchi; Norbert Vey
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

7.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Authors:  Klaus H Metzeler; Tobias Herold; Maja Rothenberg-Thurley; Susanne Amler; Maria C Sauerland; Dennis Görlich; Stephanie Schneider; Nikola P Konstandin; Annika Dufour; Kathrin Bräundl; Bianka Ksienzyk; Evelyn Zellmeier; Luise Hartmann; Philipp A Greif; Michael Fiegl; Marion Subklewe; Stefan K Bohlander; Utz Krug; Andreas Faldum; Wolfgang E Berdel; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann; Jan Braess; Karsten Spiekermann
Journal:  Blood       Date:  2016-06-10       Impact factor: 22.113

8.  Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.

Authors:  Bruno C Medeiros; Sacha Satram-Hoang; Deborah Hurst; Khang Q Hoang; Faiyaz Momin; Carolina Reyes
Journal:  Ann Hematol       Date:  2015-03-20       Impact factor: 3.673

9.  Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Authors:  Sergio Amadori; Stefan Suciu; Dominik Selleslag; Franco Aversa; Gianluca Gaidano; Maurizio Musso; Luciana Annino; Adriano Venditti; Maria Teresa Voso; Carla Mazzone; Domenico Magro; Paolo De Fabritiis; Petra Muus; Giuliana Alimena; Marco Mancini; Anne Hagemeijer; Francesca Paoloni; Marco Vignetti; Paola Fazi; Liv Meert; Safaa Mahmoud Ramadan; Roel Willemze; Theo de Witte; Frédéric Baron
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

Review 10.  'Acute myeloid leukemia: a comprehensive review and 2016 update'.

Authors:  I De Kouchkovsky; M Abdul-Hay
Journal:  Blood Cancer J       Date:  2016-07-01       Impact factor: 11.037

View more
  4 in total

Review 1.  2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies.

Authors:  Vittoria Raimondi; Giulia Ciotti; Michele Gottardi; Francesco Ciccarese
Journal:  Biomedicines       Date:  2022-06-09

2.  A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Michael Schuster; Magalie Joris; Jürgen Krauter; Johan Maertens; Dimitri Breems; Emmanuel Gyan; Tibor Kovacsovics; Amit Verma; Paresh Vyas; Eunice S Wang; Keith Ching; Thomas O'Brien; Corrado Gallo Stampino; Weidong Wendy Ma; Arthur Kudla; Geoffrey Chan; Amer M Zeidan
Journal:  Ann Hematol       Date:  2022-04-30       Impact factor: 4.030

Review 3.  Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.

Authors:  Jorge E Cortes; Priyanka Mehta
Journal:  Am J Hematol       Date:  2021-01-12       Impact factor: 10.047

4.  Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database.

Authors:  Lucia Gozzo; Calogero Vetro; Serena Brancati; Laura Longo; Daniela Cristina Vitale; Giovanni Luca Romano; Elisa Mauro; Paolo Fabio Fiumara; Cinzia Maugeri; Marina Silvia Parisi; Ilaria Dulcamare; Bruno Garibaldi; Andrea Duminuco; Giuseppe Alberto Palumbo; Francesco Di Raimondo; Filippo Drago
Journal:  Front Pharmacol       Date:  2021-11-11       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.